JP2006522800A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006522800A5 JP2006522800A5 JP2006506582A JP2006506582A JP2006522800A5 JP 2006522800 A5 JP2006522800 A5 JP 2006522800A5 JP 2006506582 A JP2006506582 A JP 2006506582A JP 2006506582 A JP2006506582 A JP 2006506582A JP 2006522800 A5 JP2006522800 A5 JP 2006522800A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- parkinson
- kit
- composition
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000018737 Parkinson disease Diseases 0.000 claims 21
- 239000000203 mixture Substances 0.000 claims 17
- 239000003795 chemical substances by application Substances 0.000 claims 14
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 10
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 10
- 229960004502 levodopa Drugs 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- NEMGRZFTLSKBAP-LBPRGKRZSA-N safinamide Chemical compound C1=CC(CN[C@@H](C)C(N)=O)=CC=C1OCC1=CC=CC(F)=C1 NEMGRZFTLSKBAP-LBPRGKRZSA-N 0.000 claims 7
- 229940099362 Catechol O methyltransferase inhibitor Drugs 0.000 claims 6
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 claims 6
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 6
- 102000010909 Monoamine Oxidase Human genes 0.000 claims 3
- 108010062431 Monoamine oxidase Proteins 0.000 claims 3
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 3
- 229960003805 amantadine Drugs 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 229950002652 safinamide Drugs 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- -1 3-fluoro-benzyloxy Chemical group 0.000 claims 2
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 claims 2
- 229960000911 benserazide Drugs 0.000 claims 2
- 238000013268 sustained release Methods 0.000 claims 2
- 239000012730 sustained-release form Substances 0.000 claims 2
- JWQHTRUIUMCHRI-SFHVURJKSA-N (2S)-2-amino-3-[4-[2-(3-fluorophenyl)ethoxy]phenyl]-2-methylpropanamide Chemical compound FC=1C=C(C=CC=1)CCOC1=CC=C(C[C@](C(=O)N)(C)N)C=C1 JWQHTRUIUMCHRI-SFHVURJKSA-N 0.000 claims 1
- WYDCYPPIJUASJE-MRXNPFEDSA-N (2r)-2-[[4-[(3-chlorophenyl)methoxy]phenyl]methylamino]-3-hydroxypropanamide Chemical compound C1=CC(CN[C@H](CO)C(=O)N)=CC=C1OCC1=CC=CC(Cl)=C1 WYDCYPPIJUASJE-MRXNPFEDSA-N 0.000 claims 1
- IEHDKRBHKAGVKZ-ZDUSSCGKSA-N (2s)-2-[(4-phenylmethoxyphenyl)methylamino]propanamide Chemical group C1=CC(CN[C@@H](C)C(N)=O)=CC=C1OCC1=CC=CC=C1 IEHDKRBHKAGVKZ-ZDUSSCGKSA-N 0.000 claims 1
- JFADNUHMEURSIM-LBPRGKRZSA-N (2s)-2-[[4-[(3-chlorophenyl)methoxy]phenyl]methylamino]propanamide Chemical compound C1=CC(CN[C@@H](C)C(N)=O)=CC=C1OCC1=CC=CC(Cl)=C1 JFADNUHMEURSIM-LBPRGKRZSA-N 0.000 claims 1
- KAWCXZXQTSSDOQ-LBPRGKRZSA-N (2s)-2-[[4-[(4-fluorophenyl)methoxy]phenyl]methylamino]propanamide Chemical compound C1=CC(CN[C@@H](C)C(N)=O)=CC=C1OCC1=CC=C(F)C=C1 KAWCXZXQTSSDOQ-LBPRGKRZSA-N 0.000 claims 1
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 claims 1
- YIZTWXJTVQAIDF-UHFFFAOYSA-N 2-[[4-[(3-bromophenyl)methoxy]phenyl]methylamino]-2-methylpropanamide Chemical compound C1=CC(CNC(C)(C)C(N)=O)=CC=C1OCC1=CC=CC(Br)=C1 YIZTWXJTVQAIDF-UHFFFAOYSA-N 0.000 claims 1
- ONJQYFDDLYSQOY-UHFFFAOYSA-N 2-[[4-[(3-chlorophenyl)methoxy]phenyl]methyl-methylamino]acetamide Chemical compound C1=CC(CN(CC(N)=O)C)=CC=C1OCC1=CC=CC(Cl)=C1 ONJQYFDDLYSQOY-UHFFFAOYSA-N 0.000 claims 1
- ZBEJIFHLSRYHPP-UHFFFAOYSA-N 2-[[4-[(3-chlorophenyl)methoxy]phenyl]methylamino]acetamide Chemical compound C1=CC(CNCC(=O)N)=CC=C1OCC1=CC=CC(Cl)=C1 ZBEJIFHLSRYHPP-UHFFFAOYSA-N 0.000 claims 1
- WKFRATOBHJEQKR-UHFFFAOYSA-N 2-amino-4-[4-[(3-chlorophenyl)methoxy]phenyl]butanamide Chemical compound C1=CC(CCC(N)C(N)=O)=CC=C1OCC1=CC=CC(Cl)=C1 WKFRATOBHJEQKR-UHFFFAOYSA-N 0.000 claims 1
- DHSSDEDRBUKTQY-UHFFFAOYSA-N 6-prop-2-enyl-4,5,7,8-tetrahydrothiazolo[4,5-d]azepin-2-amine Chemical compound C1CN(CC=C)CCC2=C1N=C(N)S2 DHSSDEDRBUKTQY-UHFFFAOYSA-N 0.000 claims 1
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 claims 1
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 claims 1
- 229960004046 apomorphine Drugs 0.000 claims 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims 1
- 229960002802 bromocriptine Drugs 0.000 claims 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims 1
- 229960004596 cabergoline Drugs 0.000 claims 1
- 229960004205 carbidopa Drugs 0.000 claims 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims 1
- KYCBWEZLKCTALM-UHFFFAOYSA-N caroxazone Chemical compound C1=CC=C2OC(=O)N(CC(=O)N)CC2=C1 KYCBWEZLKCTALM-UHFFFAOYSA-N 0.000 claims 1
- 229950006044 caroxazone Drugs 0.000 claims 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 1
- 229960003337 entacapone Drugs 0.000 claims 1
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 claims 1
- 229960003587 lisuride Drugs 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 229960004851 pergolide Drugs 0.000 claims 1
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 229960003089 pramipexole Drugs 0.000 claims 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims 1
- BHJIBOFHEFDSAU-LBPRGKRZSA-N ralfinamide Chemical compound C1=CC(CN[C@@H](C)C(N)=O)=CC=C1OCC1=CC=CC=C1F BHJIBOFHEFDSAU-LBPRGKRZSA-N 0.000 claims 1
- 229960000245 rasagiline Drugs 0.000 claims 1
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 claims 1
- 229960001879 ropinirole Drugs 0.000 claims 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 claims 1
- 229960003179 rotigotine Drugs 0.000 claims 1
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 claims 1
- 229960003946 selegiline Drugs 0.000 claims 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims 1
- 229940001089 sinemet Drugs 0.000 claims 1
- 229960004603 tolcapone Drugs 0.000 claims 1
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical group C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46220503P | 2003-04-11 | 2003-04-11 | |
| PCT/IB2004/001408 WO2004089353A2 (en) | 2003-04-11 | 2004-04-08 | Methods for treatment of parkinson's disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012273371A Division JP2013067647A (ja) | 2003-04-11 | 2012-12-14 | パーキンソン病を治療するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006522800A JP2006522800A (ja) | 2006-10-05 |
| JP2006522800A5 true JP2006522800A5 (enExample) | 2007-06-28 |
Family
ID=33159845
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006506582A Pending JP2006522800A (ja) | 2003-04-11 | 2004-04-08 | パーキンソン病を治療するための方法 |
| JP2012273371A Pending JP2013067647A (ja) | 2003-04-11 | 2012-12-14 | パーキンソン病を治療するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012273371A Pending JP2013067647A (ja) | 2003-04-11 | 2012-12-14 | パーキンソン病を治療するための方法 |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US8283380B2 (enExample) |
| EP (2) | EP1613296B1 (enExample) |
| JP (2) | JP2006522800A (enExample) |
| KR (2) | KR101129015B1 (enExample) |
| CN (2) | CN1771030A (enExample) |
| AR (1) | AR044007A1 (enExample) |
| AT (1) | ATE435012T1 (enExample) |
| AU (1) | AU2004228782B2 (enExample) |
| BR (1) | BRPI0409364A (enExample) |
| CA (1) | CA2523188C (enExample) |
| CY (3) | CY1109295T1 (enExample) |
| DE (1) | DE602004021790D1 (enExample) |
| DK (2) | DK2070526T3 (enExample) |
| ES (2) | ES2326373T3 (enExample) |
| FR (1) | FR15C0054I2 (enExample) |
| HU (1) | HUS1500043I1 (enExample) |
| IL (2) | IL171331A (enExample) |
| LU (1) | LU92782I2 (enExample) |
| MX (1) | MXPA05010873A (enExample) |
| NL (1) | NL300752I2 (enExample) |
| NO (3) | NO334316B1 (enExample) |
| NZ (1) | NZ542910A (enExample) |
| PL (2) | PL2070526T3 (enExample) |
| PT (2) | PT2070526E (enExample) |
| RU (1) | RU2342929C2 (enExample) |
| SI (2) | SI2070526T1 (enExample) |
| TW (1) | TWI340640B (enExample) |
| WO (1) | WO2004089353A2 (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9727523D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Alpha-aminoamide derivatives useful as analgesic agents |
| CN1274306C (zh) | 2001-09-03 | 2006-09-13 | 纽朗制药有限公司 | 包含加巴喷丁或其类似物和α－氨基酰胺的药物组合物及其止痛应用 |
| EP1438956A1 (en) * | 2003-01-16 | 2004-07-21 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful as antimigraine agents |
| US20070276046A1 (en) * | 2003-08-25 | 2007-11-29 | Patricia Salvati | Alpha-Aminoamide Derivatives Useful as Anti-Inflammatory Agents |
| EP1588704A1 (en) | 2004-04-22 | 2005-10-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders |
| RS51411B (sr) * | 2004-09-10 | 2011-02-28 | Newron Pharmaceuticals S.P.A. | Upotreba (r)-(halobenziloksi) benzilamino-propanamida kao selektivnih modulatora natrijumovih i/ili kalcijumovih kanala |
| US20070004639A1 (en) * | 2005-07-01 | 2007-01-04 | Bodybio, Inc. | Methods and compositions for treating Parkinson's disease |
| US8772346B2 (en) | 2005-11-09 | 2014-07-08 | Torrent Pharmaceuticals Limited | Pharmaceutical composition |
| IN266803B (enExample) | 2005-12-22 | 2015-06-03 | Newron Pharm Spa | |
| CN101032474B (zh) * | 2006-03-06 | 2011-02-16 | 重庆医药工业研究院有限责任公司 | 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法 |
| EP1870097A1 (en) * | 2006-06-15 | 2007-12-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders |
| US8106056B2 (en) * | 2006-06-16 | 2012-01-31 | Solvay Pharmaceuticals B.V. | Combination preparations comprising bifeprunox and a dopamine agonist |
| KR101491541B1 (ko) | 2006-06-19 | 2015-02-09 | 뉴론 파마슈티칼즈 에스. 피. 에이. | 2-［4-(3- 및 2-플루오로벤질옥시)벤질아미노)프로판 아미드의 제조방법 |
| DE102007014947B4 (de) * | 2007-03-23 | 2010-05-27 | Axxonis Pharma Ag | Stabilisierte wässrige Lösungen von Ergolinverbindungen |
| EP2150239A1 (en) * | 2007-04-24 | 2010-02-10 | Boehringer Ingelheim International GmbH | Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof |
| TR201802576T4 (tr) * | 2007-06-15 | 2018-03-21 | Newron Pharm Spa | Sübsti̇tüe edi̇lmi̇ş 2-[2-(feni̇l)eti̇lami̇no]alkanami̇t türevleri̇ ve bunlarin sodyum ve/veya kalsi̇yum kanal modülatörleri̇ olarak kullanimi |
| GB2453770A (en) * | 2007-10-19 | 2009-04-22 | Reckitt Benckiser Healthcare | Oral composition comprising a cooling agent |
| US20090149544A1 (en) * | 2007-10-22 | 2009-06-11 | Concert Pharmaceuticals, Inc. | Alpha-aminoamide derivatives |
| EP3257842B1 (en) | 2007-12-11 | 2020-11-18 | Newron Pharmaceuticals S.p.A. | Therapeutic use of 2-[4-(3- or 2-fluorobenzyloxy)benzylamino]propanamides with high purity degree |
| CN101903021B (zh) * | 2007-12-19 | 2012-11-14 | 纽朗制药有限公司 | 用于治疗精神病的α-氨基酰胺衍生物 |
| US20110027354A1 (en) * | 2008-04-01 | 2011-02-03 | Kim Hyoung-Chun | Anti-parkinsonian compounds |
| PL2285769T3 (pl) | 2008-06-02 | 2015-01-30 | Generics Uk Ltd | Sposób otrzymywania enancjomerycznie czystych amin |
| AU2009254929B2 (en) * | 2008-06-02 | 2014-03-13 | Generics [Uk] Limited | An improved process for the preparation of amines |
| RU2540470C9 (ru) * | 2008-06-06 | 2015-07-20 | Фарма Ту Б Лтд. | Фармацевтические композиции для лечения болезни паркинсона |
| EP2296462A4 (en) * | 2008-06-13 | 2011-06-15 | Teva Pharma | RASAGILINE FOR INFLUENCING MORBUS PARKINSON |
| WO2010010138A1 (en) * | 2008-07-24 | 2010-01-28 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising pramipexole and a calcium channel blocker for the treatment of parkinson's disease |
| US20100189790A1 (en) * | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline formulation |
| EP2218444A3 (en) * | 2009-01-23 | 2010-08-25 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline formulation |
| EP2314569A1 (en) | 2009-10-22 | 2011-04-27 | Merck Patent GmbH | Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof |
| CN102048717B (zh) * | 2009-10-29 | 2014-02-19 | 重庆医药工业研究院有限责任公司 | 一种稳定的雷沙吉兰组合物 |
| WO2011098456A1 (en) | 2010-02-09 | 2011-08-18 | Merck Serono S.A. | Safinamide in the treatment of dyskinesia |
| LT2563355T (lt) | 2010-04-27 | 2016-09-26 | Newron Pharmaceuticals S.P.A. | Ralfinamido metansulfonato druskų arba jų r-enentiomerų gavimo būdas |
| JP5820469B2 (ja) | 2010-04-30 | 2015-11-24 | テイコク ファーマ ユーエスエー インコーポレーテッド | プロピニルアミノインダンの経皮組成物 |
| EP2688561B1 (en) | 2011-03-24 | 2018-08-22 | Teikoku Pharma USA, Inc. | Transdermal compositions comprising an active agent layer and an active agent conversion layer |
| US20150031768A1 (en) * | 2011-08-19 | 2015-01-29 | The Trustees Of Princeton University | C-halogen bond formation |
| WO2013028639A1 (en) | 2011-08-19 | 2013-02-28 | The Trustees Of Princeton University | C-halogen bond formation |
| EP2776020B1 (en) | 2011-11-09 | 2019-09-11 | Teikoku Seiyaku Co., Ltd. | Methods for the treatment of skin neoplasms |
| RU2685718C2 (ru) | 2012-10-22 | 2019-04-23 | Сивитас Терапьютикс, Инк. | Лекарственные формы леводопы для быстрого купирования болезни паркинсона |
| JP6050896B2 (ja) | 2012-11-02 | 2016-12-21 | テイコク ファーマ ユーエスエー インコーポレーテッド | プロピニルアミノインダン経皮組成物 |
| US9155695B2 (en) | 2013-03-14 | 2015-10-13 | Medtronic, Inc. | Injectable ropinirole compositions and methods for making and using same |
| US10111879B2 (en) | 2013-06-27 | 2018-10-30 | Cedars-Sinai Medical Center | Adrenoceptors antagonists for the prevention and treatment of neurodegenerative conditions |
| CN106659685B (zh) * | 2014-04-21 | 2021-02-05 | 丝维塔斯治疗公司 | 快速减轻帕金森病中的运动波动 |
| WO2016052928A1 (ko) * | 2014-10-02 | 2016-04-07 | 한국과학기술연구원 | 알파-아미노아미드 유도체 화합물 및 이를 포함하는 약학적 조성물 |
| KR20180041234A (ko) * | 2015-08-27 | 2018-04-23 | 프렉스톤 테라퓨틱스 에스에이 | 레보도파로 유발된 이상운동증 치료용 뇌 침투성 크로몬 옥심 유도체 |
| KR102889062B1 (ko) * | 2016-03-17 | 2025-11-21 | 더 존스 홉킨스 유니버시티 | Paris의 파네실화에 의해 파킨슨병을 예방 또는 치료하기 위한 방법 |
| ITUA20163981A1 (it) | 2016-05-31 | 2017-12-01 | Zambon Spa | Composizioni farmaceutiche comprendenti safinamide |
| EP3568082A4 (en) * | 2017-01-14 | 2020-12-09 | Neurrx, SPC | METHOD OF USE OF HUMAN EXCREMENTS AND SECRETIONS FOR THE EARLY DETECTION OF PARKINSON'S DISEASE |
| CN109251155A (zh) * | 2017-07-14 | 2019-01-22 | 广东东阳光药业有限公司 | α-氨基酰胺衍生物及其用途 |
| CA3072994A1 (en) * | 2017-08-17 | 2019-02-21 | Zi-Qiang Gu | Pamoate salt of monoamine anti-parkinson's agents, method of preparation and use thereof |
| CA3080975A1 (en) | 2017-11-02 | 2019-05-09 | Zambon S.P.A. | Pharmaceutical compositions comprising safinamide |
| KR102005019B1 (ko) * | 2018-04-04 | 2019-07-31 | 한국과학기술연구원 | 뇌졸중의 예방 및 치료용 조성물 |
| DK4027815T5 (en) * | 2019-09-12 | 2026-08-03 | Achieve Life Sciences Inc | Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof |
| LU101477B1 (en) * | 2019-11-12 | 2021-05-14 | Univ Luxembourg | An inhibitor of an iron-containing hydrogenase of a methanogenic archaeon for use in the treatment or prevention of a parkinsonian condition |
| CN110938014A (zh) * | 2019-11-28 | 2020-03-31 | 岳千奥 | 取代苯氧酰胺衍生物、应用及用于治疗帕金森病的药物 |
| US20230028539A1 (en) * | 2019-12-06 | 2023-01-26 | Shanghai Pharmaceuticals Holding Co., Ltd. | Pharmaceutical composition, complementary kit and application thereof |
| CN110999980A (zh) * | 2019-12-19 | 2020-04-14 | 新疆石河子职业技术学院（石河子市技工学校） | 一种葡萄酒洗浸奶酪加工方法 |
| WO2022047298A1 (en) * | 2020-08-31 | 2022-03-03 | Purdue Pharma L.P. | Compositions and methods for levodopa delivery |
| KR20230154249A (ko) * | 2021-03-08 | 2023-11-07 | 프로테나 바이오사이언시즈 리미티드 | 파킨슨 질환의 치료 |
| KR102790040B1 (ko) * | 2021-06-24 | 2025-04-01 | 연세대학교 산학협력단 | 도파민 미모톱 기능 합성 펩티드 및 이를 포함하는 mao-b 억제제 |
| CN117615768A (zh) * | 2021-06-24 | 2024-02-27 | 韦斯特兰德特斯创新股份公司 | 用于帕金森病的nad增效疗法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1140748A (en) | 1966-06-23 | 1969-01-22 | Ici Ltd | New carboxylic acid derivatives |
| US3795739A (en) * | 1972-02-14 | 1974-03-05 | Hoffmann La Roche | Treatment of parkinson disease |
| US4049663A (en) | 1972-06-06 | 1977-09-20 | Allen & Hanburys Limited | Ethylene diamine derivatives |
| FR2480747A1 (fr) | 1980-04-17 | 1981-10-23 | Roques Bernard | Derives d'acides amines et leur application therapeutique |
| US4935429A (en) | 1985-10-25 | 1990-06-19 | Dackis Charles A | Method of treating psychostimulant addiction |
| DE3779500T2 (de) * | 1986-06-10 | 1993-01-21 | Chiesi Farma Spa | Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen. |
| CA1336169C (en) | 1988-03-01 | 1995-07-04 | Walther Birkmayer | Agent for treatment of parkinson's disease |
| IL94466A (en) | 1989-05-25 | 1995-01-24 | Erba Carlo Spa | Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation |
| US5221536A (en) * | 1990-05-07 | 1993-06-22 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
| US5502658A (en) | 1990-12-27 | 1996-03-26 | Relin; Arkadi | Sampled-continuous probability method of velocity measurement of the object having informatively-structural inhomogeneity |
| GB9306886D0 (en) | 1993-04-01 | 1993-05-26 | Erba Carlo Spa | Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation |
| IL111240A (en) * | 1993-10-18 | 2001-10-31 | Teva Pharma | Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them |
| DK0828513T3 (da) * | 1995-05-26 | 2004-04-13 | Pfizer | Kombinationspræparater til behandling af parkinsonisme, indeholdende selektive NMDA-antagonister |
| GB9515412D0 (en) | 1995-07-27 | 1995-09-27 | Pharmacia Spa | 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives |
| GB9727523D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Alpha-aminoamide derivatives useful as analgesic agents |
| FI109453B (fi) | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| US20020019421A1 (en) * | 2000-07-05 | 2002-02-14 | Roni Biberman | Compositions and therapy for substance addiction |
| DE10041479A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
| FR2829027A1 (fr) * | 2001-08-29 | 2003-03-07 | Aventis Pharma Sa | Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson |
-
2004
- 2004-04-07 AR ARP040101189A patent/AR044007A1/es unknown
- 2004-04-08 NZ NZ542910A patent/NZ542910A/en not_active IP Right Cessation
- 2004-04-08 PT PT91548644T patent/PT2070526E/pt unknown
- 2004-04-08 EP EP04726590A patent/EP1613296B1/en not_active Expired - Lifetime
- 2004-04-08 EP EP09154864.4A patent/EP2070526B1/en not_active Expired - Lifetime
- 2004-04-08 PL PL09154864T patent/PL2070526T3/pl unknown
- 2004-04-08 CA CA2523188A patent/CA2523188C/en not_active Expired - Lifetime
- 2004-04-08 MX MXPA05010873A patent/MXPA05010873A/es active IP Right Grant
- 2004-04-08 BR BRPI0409364-0A patent/BRPI0409364A/pt not_active Application Discontinuation
- 2004-04-08 RU RU2005131422/15A patent/RU2342929C2/ru active
- 2004-04-08 KR KR1020057019264A patent/KR101129015B1/ko not_active Expired - Lifetime
- 2004-04-08 ES ES04726590T patent/ES2326373T3/es not_active Expired - Lifetime
- 2004-04-08 AU AU2004228782A patent/AU2004228782B2/en not_active Expired
- 2004-04-08 CN CNA200480009655XA patent/CN1771030A/zh active Pending
- 2004-04-08 DK DK09154864.4T patent/DK2070526T3/da active
- 2004-04-08 DE DE602004021790T patent/DE602004021790D1/de not_active Expired - Lifetime
- 2004-04-08 DK DK04726590T patent/DK1613296T3/da active
- 2004-04-08 AT AT04726590T patent/ATE435012T1/de active
- 2004-04-08 WO PCT/IB2004/001408 patent/WO2004089353A2/en not_active Ceased
- 2004-04-08 PT PT04726590T patent/PT1613296E/pt unknown
- 2004-04-08 KR KR1020117013555A patent/KR20110070929A/ko not_active Ceased
- 2004-04-08 SI SI200432150T patent/SI2070526T1/sl unknown
- 2004-04-08 CN CN201110271872.8A patent/CN102274517B/zh not_active Expired - Lifetime
- 2004-04-08 TW TW093109755A patent/TWI340640B/zh not_active IP Right Cessation
- 2004-04-08 PL PL04726590T patent/PL1613296T3/pl unknown
- 2004-04-08 SI SI200431192T patent/SI1613296T1/sl unknown
- 2004-04-08 US US10/559,982 patent/US8283380B2/en active Active
- 2004-04-08 ES ES09154864.4T patent/ES2454272T3/es not_active Expired - Lifetime
- 2004-04-08 JP JP2006506582A patent/JP2006522800A/ja active Pending
-
2005
- 2005-10-10 NO NO20054640A patent/NO334316B1/no active Protection Beyond IP Right Term
- 2005-10-10 IL IL171331A patent/IL171331A/en active Protection Beyond IP Right Term
-
2009
- 2009-08-12 CY CY20091100857T patent/CY1109295T1/el unknown
-
2011
- 2011-11-17 IL IL216403A patent/IL216403A/en active IP Right Grant
-
2012
- 2012-08-24 US US13/594,621 patent/US8901176B2/en not_active Expired - Lifetime
- 2012-12-14 JP JP2012273371A patent/JP2013067647A/ja active Pending
-
2013
- 2013-10-28 NO NO20131417A patent/NO335537B1/no unknown
-
2014
- 2014-04-15 CY CY20141100288T patent/CY1115286T1/el unknown
- 2014-11-04 US US14/532,925 patent/US9492410B2/en not_active Expired - Fee Related
-
2015
- 2015-07-01 CY CY2015025C patent/CY2015025I2/el unknown
- 2015-07-17 NL NL300752C patent/NL300752I2/nl unknown
- 2015-07-22 LU LU92782C patent/LU92782I2/xx unknown
- 2015-07-22 HU HUS1500043C patent/HUS1500043I1/hu unknown
- 2015-07-22 FR FR15C0054C patent/FR15C0054I2/fr active Active
- 2015-07-23 NO NO2015018C patent/NO2015018I1/no not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2523188A1 (en) | Methods for treatment of parkinson's disease | |
| JP2012092127A5 (enExample) | ||
| JP2009532340A5 (enExample) | ||
| HRP20110230T1 (hr) | Derivati alfa-aminoamida korisni u tretmanu poremećaja uzrokovanih ovisnošću | |
| EA200600222A1 (ru) | Применение ротиготина для лечения депрессии | |
| PL1656122T3 (pl) | Transdermalne preparaty lecznicze zawierające połączenia substancji czynnych do leczenia choroby Parkinsona | |
| JP2011522035A5 (enExample) | ||
| JP2009533356A5 (enExample) | ||
| JP2008501776A5 (enExample) | ||
| CA2512683A1 (en) | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | |
| BRPI1008727B8 (pt) | derivado de azol substituído, inibidor de monoamina-oxidase b (maob) e composição farmacêutica contendo os derivadospara o tratamento de doença de parkinson | |
| JP2019052163A5 (enExample) | ||
| BR112013001422A2 (pt) | metodo para tratar ou previnir disturbios induzidos por l-dopa, agonista dopamina e/ou acentuador de dopamina em um individuo que necessita dos mesmos, agente, composição, uso de ou mais agentes e metodo para tratar a doença de parkinson | |
| JP2005523334A5 (enExample) | ||
| JP2007509146A5 (enExample) | ||
| RU2005137704A (ru) | 3-фторпиперидины в качестве антагонистов nmda/nr2b | |
| MX2010001702A (es) | Farmaco para aliviar las complicaciones motoras o los sintomas psiquiatricos de la enfermedad de parkinson. | |
| WO2006037061A3 (en) | Compositions and methods of using d-dopa to treat parkinson's disease | |
| EP3823607A4 (en) | ADMINISTRATION OF LEVODOPA AND DOPA DECARBOXYLASE INHIBITOR INTO THE RESPIRATORY TRACT FOR THE TREATMENT OF PARKINSON'S DISEASE | |
| TWM422413U (en) | Clamping type roller massage device | |
| US20090247537A1 (en) | Methods for preventing or treating bruxism using dopaminergic agents | |
| JP2007511577A5 (enExample) | ||
| UA94043C2 (ru) | Применение агомелатина в получении лекарственных средств, предназначенных для лечения перивентрикулярной лейкомалации | |
| Jain et al. | A REVIEW ON DRUGS USE IN TREATMENT OF PARKINSON’S | |
| Gohil | Steady progress on Parkinson’s disease |